Pin Site Infection Prevention for Open Tibial Fracture

Sponsor
Prince of Songkla University (Other)
Overall Status
Completed
CT.gov ID
NCT01017094
Collaborator
(none)
30
1
1
26
1.2

Study Details

Study Description

Brief Summary

This study aimed to compare the efficacy of pin-tract infection prevention between silversulfadiazine and dry dressing.

Methods: 30 patients with an open tibial fracture admitted to Songklanagarind hospital from September 2007 to June 2008 and treated by emergency debridement and external fixation were randomized into two groups, one treated with silversulfadiazine for infection prophylaxis (15) and a control group treated with dry dressing only (15). All patients were followed until the external fixator was removed. Pin-site infections were assessed and graded at each follow-up visit by an orthopaedist blinded to the mode of treatment. A culture from the pin site was done if an infection occurred.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Can Silversulfadiazine Prevent Pin-site Infection in Open Tibial Fracture?: A Randomized Controlled Trial
Study Start Date :
Sep 1, 2007
Actual Primary Completion Date :
Jun 1, 2008
Actual Study Completion Date :
Nov 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: dry dressing

local application

Drug: silversulfadiazine
apply once a day

Outcome Measures

Primary Outcome Measures

  1. incidence of pin site infection [2 years]

Secondary Outcome Measures

  1. type of organism [2 years]

  2. severity of pin site infection [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Open tibial fracture treated with external fixator age between 15-60 years
Exclusion Criteria:
  • Immunocompromised patients (diabetes, HIV or malignancy)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Prince of Songkla University Hat Yai Songkhla Thailand 90110

Sponsors and Collaborators

  • Prince of Songkla University

Investigators

  • Principal Investigator: Boonsin Tangtrakulwanich, MD.,Ph.D, Faculty of Medicine, Prince of Songkla University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01017094
Other Study ID Numbers:
  • EC 50/369-006
First Posted:
Nov 20, 2009
Last Update Posted:
Nov 20, 2009
Last Verified:
Nov 1, 2009

Study Results

No Results Posted as of Nov 20, 2009